Learner | Investor | Traveller | Fitness
Thane, Maharashtra
Joined January 2011
- Tweets27.6K
- Following225
- Followers10.1K
- Likes31.8K
Pinned Tweet
The market hasn't been oversold this bad since COVID crash of 2020. Arguably market was not expecting another war and it is getting priced in. No one knows, what will be the consequences of US Iran conflict and when will the Crude price stabilize?
Similar sentiments were there in 2020, when global lockdown happened during Covid. That time it seemed most businesses would shut or report huge losses. What actually followed was longest bull run in recent times, exceeding the expectations of all and sundry.
Those who were pessimistic paid huge opportunity cost that time.
Stock price would always follow the earnings growth momentum, come want may. With at least 2 year time frame, this fall is another great opportunity to accumulate quality companies with PEG ratio of around 0.5. Many opportunities exist in this range today.
Lastly, I will not be biased this time that only small caps can generate alpha. I am not ignoring quality mid and large caps.
Senores Pharma
Good and consistent Q2 results. Management guidance remains 50% so H2 should be better and stronger.
Senores Pharma ~ Good Q1FY27 YoY/ flat QoQ
→ Strong revenue growth delivered in Regulated & Emerging markets with revenue growth of 42% & 30% respectively on a YoY basis.
→ EBIDTA for Q1FY27 grew by 87% with margin expansion of ~800 bps on a YoY basis.
→ Nearly doubled Regulated Markets portfolio, expanding from 30 ANDAs as of June 2025 to 58 approved ANDAs as of June 2026, out of which 23 ANDAs have been commercialized.
→ The addition of Baroda-based USFDA approved manufacturing plant enhances scalability, deepens access to Regulated Markets, enables accelerated product launches, improves operating leverage, margins, and expands CDMO & CMO opportunities, positioning Senores for sustained growth.
→ Production is already ramped up at Apnar facility, with full scale-up and further expansion is expected over the next 12-18 months.
Morepen Lab
Excellent Q2FY27 Nos. YoY and QoQ
PAT more than doubles YoY
Margins doubles YoY and improves QoQ
Morepen Laboratories — Q2FY27 Results 🔔
#Q2Results #Q2FY27 #Morepen
Revenue ₹746.50 Cr vs ₹411.58 Cr
(+81.38% YoY┃+30.94% QoQ)
EBITDA ₹123.12 Cr vs ₹30.69 Cr
(+301.10% YoY┃+49.17% QoQ)
EBITDA Margin 16.49% vs 7.46% YoY & 14.48% QoQ
PBT (Excl. Exceptional) ₹116.54 Cr vs ₹19.87 Cr
(+486.52% YoY┃+56.37% QoQ)
PAT ₹88.89 Cr vs ₹41.04 Cr
(+116.58% YoY┃+57.76% QoQ)
PAT After Minority interest ₹88.89 Cr vs ₹40.87 Cr
(+117.48% YoY┃+57.62% QoQ)
Other Income ₹8.69 Cr vs ₹4.64 Cr YoY & ₹5.18 Cr QoQ
In Q2FY26 Exceptional Gain of ₹25.82 Cr
Morepen Lab
CDMO revenue rose to Rs. 253 Cr in Q2 FY27 from Rs. 58 Cr in Q1 FY27 as CDMO moved to commercial scale.
First phase of API + CDMO capacity completed at 614 KL; next phase towards 800 KL targeted for Q2 FY28
CAPACITY EXPANSION
Morepen says the first phase of its API + CDMO capacity expansion has been completed at 614 KL, ahead of schedule, up from approximately 535 KL.
Morepen submitted its first U.S. ANDA for Sitagliptin Tablets USP during the quarter, strengthening its finished-dosage development and regulatory capabilities.
Morepen Lab management highlights 3 pillars of future growth
CDMO - big lever for future growth and expansion
API - new molecules have better margin profile
Medical device - market Leadership with strong momentum maintained
youtu.be/sS5Ik4HCW7Q?si=84YJ…
Laurus Labs delivered blockbuster Q1FY27, followed by bullish concall
▪️Revenue growth of 29%
▪️EBIDTA margin expansion of 7%
▪️Net profit & diluted EPS grew 126% & 127%
▪️First ever 2000 cr revenue in a quarter
Laurus Labs Q1 Earnings Call
Key takeaways:
💊 CDMO revenue run-rate of ₹835 Cr/qtr expected to sustain, with potential to stay around ₹1,000 Cr/qtr
💊 FY27 capex raised to ₹2,000 Cr (from ₹1,500 Cr last quarter; initial guidance was ₹1,000 Cr)
💊 Capex increase backed by strong customer demand & revenue visibility, unlike previous capacity-led expansions
💊 Management reiterated ≥1.0x gross asset turnover guidance
💊 55% of CDMO revenue is from commercial products, while the balance is largely Phase 3 supplies more commercial conversions expected ahead
💊 Confident of 50%+ revenue contributionfrom CDMO by FY30
💊 Multiple GLP opportunities under development; peptides expected to becomea meaningful growth driver
💊 Revenue remains well diversified, with no concentration
Source : DAM capital
RR Kabel
🎯 Strategic acquisition by the company (gradual shift from low margin house wires segment and competition from Ultra Volt)
➤ Board has approved acquiring the Optical Fibre Cable business undertaking of U M Cables Ltd (a wholly-owned subsidiary of Usha Martin) on a slump sale.
➤ This marks the company's entry into the Optical Fibre Cable segment, with ready manufacturing assets, existing approvals and an operating track record.
RR Kabel reported steller Q2 results with revenue ₹3284Cr (+51.77% YoY) and PAT ₹180.60 Cr (+55.29% YoY).
However it cut FY27 volume growth guidance to 14-16%, vs 18% earlier which made the stock fall today by 4%.
#RRKabel cuts FY27 volume growth guidance to 14-16%, maintains margin outlook
cnbctv18.com/market/earnings…
JPL Free float is ~2.9-3% of the ~₹12.5 lakh crore total market cap. That leaves only ~₹37-39k crore of shares actually tradable.
Low float = thin liquidity, so the stock can swing sharply either way like a mid-cap even though the headline valuation is as huge as mega cap.
Raymond Ltd.
✅ Good Q2FY27 nos
▪️Revenue and PBT growing 21% & 130% YoY
▪️Good margin expansion of 370bps YoY (3.4% to 6.1%)
▪️Aerospace and Defense revenue grew 72%
▪️Precision manufacturing grew by 15% and has been lagging the growth
▪️CFO turned positive from (33cr) to 50cr
Raymond Management's commentary in the concall today
➤ Growth Targets: Raymond aims for sustained growth in high-mid 20% range.
➤ Capacity Expansion: Bangalore aerospace facility targeting Rs.700-750 crore revenue; Andhra Pradesh greenfield plant on track for Q3 FY28.
➤ Order Pipeline: Robust RFQs across aerospace and precision engineering indicate healthy pipeline.
➤ Challenges: Geopolitical tensions affect logistics and raise costs; inflationary pressures from commodity prices persist despite pass-through contracts.
Operational Scaling: Increased R&D expenses and initial rejection rates in aerospace impacting profitability short-term.
Fantastic listing by JPL being a mega cap.
MOFSL and Nomura initiate buying on Jio Platforms Ltd. (JPL) with 20% upside and price target is achieved on the listing day itself.
Sky Gold and Diamonds saw steller rally before the results and profit booking is expected.
Now it is appraching 50dma levels of 850, it has seen reversal from these level since March rally.
Sky Gold and Diamonds
✅ Blockbuster Q2FY27 YoY and QoQ
The Board has considered and approved raising of funds for an aggregate amount upto and not exceeding Rs. 1,800 crore through QIP.
Good Q2FY27 results and tracking
Bajaj Consumer Care - FMCG could be a comeback theme
Solara Activ Pharma
Bajaj Health Care
E2E Network
Ujjivan SFB
SG Finserv
Polycab - copper price impacted PAT margin
The Defence Acquisition Council (DAC), the highest decision-making body on defence procurement in the Ministry of Defence, is set to consider proposals worth over Rs 1 lakh crore at a key meeting scheduled for Friday, July 3. According to sources in the Ministry of Defence, it is expected to be one of the most significant DAC meetings in recent times.
ndtv.com/india-news/defence-…
the DAC granted Acceptance of Necessity for various capital acquisition proposals. The total worth of these proposals is approximately Rs 2,12,000 crore for the armed forces. A significant portion, about 82%, will be sourced from the Indian industry to promote domestic procurement
m.economictimes.com/news/def…
List of beneficiaries of 2.12 lakh crore DAC proposal
Key potential beneficiaries of the Rs 2.12 lakh crore DAC AoNs (82% from Indian industry):
HAL (helicopters), BEL (C-UAS, radars, air defence, electronics), L&T (self-propelled guns/K9 Vajra), BDL (VSHORADS), BEML (high mobility vehicles), Zen Technologies/ideaForge/Paras Defence/Data Patterns (UAVs, kamikaze drones, counter-drone systems), Mazagon Dock/Cochin Shipyard/GRSE (naval platforms).
AoN is only initial approval; contracts take time. Not financial advice.
I saw some social media posts couple of months back, recommending to invest in Brazil as a new destination of emerging markets.
Now Indian market looks more resilient as compared to them.
